American Diabetes Association
Research Programs

November 2022

Innovative Transformational Research to Reduce Health Disparities and Advance Health Equity in Diabetes
Innovative Clinical or Translational Science Award

Letter of Inquiry (LOI) Instructions
https://professional.diabetes.org/research-grants
grantquestions@diabetes.org
# Table of Contents

## I. HEALTH DISPARITIES INNOVATIVE CLINICAL OR TRANSLATIONAL SCIENCE AWARD

- A. DEADLINE ......................................................................................................................... 2
- B. INSTITUTIONAL APPROVAL .......................................................................................... 2
- C. NOTIFICATION ............................................................................................................... 2
- D. GRANT SUPPORT ........................................................................................................... 2
- E. REVIEW CRITERIA .......................................................................................................... 2
  - Eligibility Stipulations .................................................................................................. 3
  - Faculty Appointment ...................................................................................................... 3
  - Other Sources of Support ............................................................................................. 3
  - Open Data and Resource Sharing ............................................................................... 3
  - Institutional Assurances ............................................................................................... 4
  - Confirmation of Study Drug ......................................................................................... 4
- F. BUDGET GUIDELINES .................................................................................................... 4
  - Salary for Principal Investigator ................................................................................. 4
  - Technical Personnel ...................................................................................................... 4
  - Subcontracts .................................................................................................................. 4
  - Supplies ........................................................................................................................... 5
  - Equipment ....................................................................................................................... 5
  - Other Expenses .............................................................................................................. 5
  - Prohibited Expenses ...................................................................................................... 5
  - Indirect Costs .................................................................................................................. 5
  - Overlapping Funding ..................................................................................................... 5

## II. ONLINE INSTRUCTIONS ............................................................................................... 6

- A. PRINCIPAL INVESTIGATOR .......................................................................................... 6
  - Contact Information ....................................................................................................... 6
  - ORCID Identifier ............................................................................................................ 6
  - American Diabetes Association Membership ............................................................. 6
  - Work Permission ........................................................................................................... 6
- B. REQUESTED BUDGET .................................................................................................. 7
- C. PROJECT DETAILS ....................................................................................................... 7
  - Resubmissions ............................................................................................................... 7
  - Title of Proposal ............................................................................................................ 8
- D. PROJECT SUMMARY .................................................................................................. 8
  - Research Type ............................................................................................................... 8
  - Diabetes Type of Proposed Research ........................................................................... 8
  - Therapeutic Goal ............................................................................................................ 8
  - Research Program Area ................................................................................................. 8
  - Scientific Abstract ......................................................................................................... 9
  - Lay Abstract ................................................................................................................... 9
  - RFA Alignment .............................................................................................................. 9

## III. RESEARCH PLAN ......................................................................................................... 10

- A. FILE FORMAT ............................................................................................................... 10
- B. FORMATTING REQUIREMENTS .................................................................................. 10
- C. RESEARCH PLAN CONTENTS ..................................................................................... 10
  1) Research Plan (2-page maximum) ............................................................................ 10

## IV. LETTER OF INQUIRY SUBMISSION .......................................................................... 12

## V. QUESTIONS? CONTACT US ...................................................................................... 12
I. Health Disparities Innovative Clinical or Translational Science Award

The American Diabetes Association is requesting letters of inquiry (LOIs) for research focused on the impact of diabetes on health disparities and, the impact of health disparities on diabetes and its complications.

**Background:** According to the U.S. Department of Health and Human Services, health disparities are defined as: *differences in health that are closely linked with social or economic disadvantage*. Health disparities adversely affect groups of people who have systematically experienced greater social and/or economic obstacles to health based on their racial or ethnic group; religion; socioeconomic status; gender; age; mental health; cognitive, sensory, or physical disability; sexual orientation; geographic location; or other characteristics historically linked to discrimination or exclusion.

**Goal:** The American Diabetes Association seeks to provide critical funding toward innovative transformational and translatable research with significant potential to reduce health disparities and advance health equity in the lives of people living with diabetes and its complications.

**Scope:** For this funding opportunity, attention must focus on, and all hypotheses should reflect, the impact of race/ethnicity, socioeconomic status, health care access, and/or other direct factors that underlie diabetes health disparities, and describe how results will transform assessment and treatment of underserved groups and address significantly improved outcomes in diabetes or its complications. We encourage formative research, intervention development, and/or pilot-testing of interventions. For the purposes of this RFA, we encourage interventions that include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent and/or improve clinical outcomes for persons living with diabetes or it’s complications.

Importantly, applicants should clearly indicate how the proposed research, if successful, will have a significant impact (“move the needle”) the development, dissemination, or implementation of innovative and effective interventions and/or strategies that reduce health disparities and advance health equity in diabetes.

*Applications that do not directly address the defined scope of the RFA will be triaged and not move forward to peer review.*

High-level priorities:

1. Clinical investigations aimed at defining the optimal therapeutic approaches or studies identifying the effect of treatment approaches to address of diabetes or its related complications.
2. Studies to improve effective strategies to improve health care delivery for persons with diabetes or its related complications, including the development of improved clinical decision support tools.
3. Studies investigating social, behavioral, or built environment on diabetes prevention or control. Dissemination and implementation studies in health care systems or marginalized populations and structural inequalities

Clinical research is defined as research where the effect of health disparities on diabetes and its complications is evaluated, and includes therapeutic interventions, health services/care delivery research and epidemiological research aimed at identifying the distribution and determinants of disease in a population.

Translational research supported through this mechanism will typically involve expertise, collaboration and engagement across disciplines, and falls into two broad categories, (1) translating basic biological discoveries about how chronic discrimination can alter diabetes metabolism into clinical applications that improve human health, and (2) accelerating the translation of advances from research in health disparities on diabetes and its complications to the community setting or enhancing the adoption of best practices in patient care.
A. **Deadline**

The submission deadline for this LOI is **June 27, 2022** for anticipated November 15, 2022 funding. Electronic letters of inquiry (LOIs) must be submitted online via the official Grant Management Site by 5:00 PM Eastern Time on the deadline date.

B. **Institutional Approval**

The applicant, also referred to as the Principal Investigator (PI), must have the institution’s approval prior to applying electronically. Although written confirmation is not required, PI must ensure that the Sponsoring Institution is aware of the grant and has acknowledged its intent to fully support the award. In addition, PI must attest that the grant has been routed through, and approved by, the usual administrative channels of the Sponsoring Institution.

C. **Notification**

Upon application submission, the applicant will be sent a confirmation of receipt for their Letter of Inquiry submission via email. Applicants will receive updates on the status of their LOI in July 2022. This notification will be sent to the applicant’s email address as entered into the online application form. If the PI does not receive a confirmation email within the indicated time frame, please contact grantquestions@diabetes.org.

D. **Grant Support**

The ADA Innovative Clinical or Translational Science Award provides up to $200,000 per year for up to three years. The total award amount (direct plus indirect costs) cannot exceed $600,000 for a three-year award, and the yearly total amount (direct plus indirect cost) cannot exceed $200,000. Indirect costs cannot exceed 10% of requested direct costs.

Award funds must be used for research activities in the described project and are to be divided between the salary and project support. Support for the PI’s yearly salary (including fringe benefits) cannot exceed 20% of total costs (direct plus indirect). Research support may be used to defray the costs of a postdoctoral fellow, technician, supplies, equipment, travel, etc. Refer to the Budget Guidelines for specifics regarding allowable expenses.

E. **Review Criteria**

Letters of Inquiry will be evaluated on the potential of the project to impact knowledge of health disparities on diabetes and its ultimate translation to advance prevention, intervention, or treatment. Originality and degree of scientific rigor in study design, scientific precision and potential clinical impact of the project, applicability to the scope of the RFA and the potential impact on advancing the understanding diabetes and health disparities are all important to consider. Relevant experience of the Principal Investigator, availability of the appropriate facilities and resources, the ability of the investigator/site to recruit the patient population, access to, and availability of, data sources, samples and study medications (if applicable) and for fellowships, relevant experience and training history of the Mentor, are also pertinent. The specific timeline for progress of enrollment, data analyses and/or other major project milestones and an appropriate budget allowing for the completion of the proposed work need to be stated.
Eligibility Stipulations
Applicant must hold a PhD, MD, PharmD, DO or DPM degree or, for other health professionals, the equivalent doctoral-level health- or science-related degree, and possess the necessary skills and training to carry out the proposed work.

Awards are limited to institutions within the United States and U.S. possessions. All investigators must be legally authorized to work in the U.S. Institutional confirmation of permission to work within the U.S. will be required for all applicants at the time of submission.

One person must be specified as the Principal Investigator; multiple PIs/co-PIs are not permitted.

Individuals may not currently hold another active ADA Award.

Faculty Appointment
At the time of submission, ADA Innovative Clinical or Translational Science Award applicants must hold a full-time independent faculty position or the equivalent at a university, university-affiliated research institution or other non-profit research institution. If an appointment is less than full-time, it must be noted on the budget page and fully explained on the budget justification page. Letters of inquiry (LOIs) from PIs with less than a full-time appointment will be considered on a case-by-case basis.

Applicants from non-university research institutions must provide a letter from the proper institutional official to explain how the position of the applicant compares to a faculty position in a traditional academic institution. Any ambiguity about the applicant’s position can negatively impact the letter of inquiry (LOI).

Other Sources of Support
Applicants must agree to devote sufficient time and effort to research to accomplish the aims of the proposal during the period of ADA funding.

Investigator Funding Cap
*Due to fiscal constraints in research funding, the Association limits applicant eligibility to maximally support early career investigators and investigators at a higher level of need to maintain their existing research programs.*

Investigators with support as PI exceeding $500,000 in direct costs per submission year are not eligible to apply. Non-profit/foundation, government, and investigator-initiated pharmaceutical/industry awards count toward the $500,000 funding cap, but multi-center and industry-sponsored clinical trial grants are excluded from calculation.

Applicants cannot hold or apply for more than one Association Award at a time. Investigators currently funded through the Association’s Research Programs cannot apply for additional support unless the existing award expires by the funding start date of the new award.

Open Data and Resource Sharing
All data resulting from ADA-funded research that can be shared without compromising human subject protections must be shared to an approved open data repository within 6 months of publication or within 18 months of the conclusion of the funding period, if the study remains unpublished.
A listing of repositories recommended by NIH is available on our website under ADA-Funded Research. Awardees are encouraged to use the repository most appropriate for the subject matter of the research conducted.

Resources developed with ADA grant funding are required to be made available to the broader scientific community. ADA-funded projects expected to generate unique model organism resources or genomic data must include specific plans during the full application process for sharing and distributing. If sharing is not possible, funded applicants will be required to provide an acceptable explanation and request for waiver.

In general, to the extent possible, ADA grantees are expected to share all scientific resources upon request for the advancement of research progress. While the data and resource sharing plan will not impact the application score, it is a requirement for submission.

**Institutional Assurances**

The ADA requires IRB and IACUC assurances for human and animal subjects, respectively, if these are used in the funded research experiments/protocols. Funded applicants must provide IRB and/or IACUC approval and submit documentation of approval(s) during the full application process or by the start date of the award. Award activation is contingent upon submission of proof of approval. If approval(s) are not received by the award start date, the award letter will not be provided.

**Confirmation of Study Drug**

If the proposed research requires drug or drug placebo, the investigator must demonstrate having access to the needed research supplies by submitting documentation during the full application process or by the start date of the award. Award activation is contingent upon submission of proof of approval. If approval(s) are not received by the award start date, the award letter will not be provided.

**F. Budget Guidelines**

**Salary for Principal Investigator**

PI salary support, including fringe benefits, cannot exceed 20% of total costs per year. ADA staff assumes that appointments at the applicant’s organization are full-time. If an appointment is less than full-time, it must be indicated with an asterisk (*) on the Budget form and fully explained on the Budget Justification page.

**Technical Personnel**

Technical personnel can receive salary from an ADA grant in accordance with the percent effort on the grant and within allowable institutional salary guidelines. Technical personnel include any individuals working on the research project in a scientific or technical capacity. For example, collaborating investigators, postdoctoral fellows, lab technicians, nurses, statisticians, and patient recruiters are all considered technical personnel. Administrative, secretarial, and/or custodial employees are not considered technical personnel and are ineligible to receive support from an ADA grant. If technical personnel have not yet been hired or identified, simply note that the person is “TBD” (to be determined). As soon as additional personnel have been identified, PI must provide the ADA with the biographical sketch of individuals holding a graduate level degree or above.

**Subcontracts**

During the full application process, individual subcontracts must be indicated on the main budget page and itemized subcontract budgets must be provided on a separate budget page. Any indirect costs associated with a subcontract must be incorporated into the overall budget’s yearly maximum indirect costs allowed (i.e., 10% of total direct costs) in the main budget. The combined indirect costs for the grant and any subcontracts cannot exceed the 10% maximum indirect rate allowed for the award.
Supplies
There is no limit on the amount of budget funds that can be used for laboratory/research supplies. A categorized supply list must be included on the budget form and required financial reports submitted during the full application process. Office supplies are not permitted to be categorized as a direct cost.

Equipment
The Association defines equipment as any item costing more than $5,000 with a lifespan of two or more years. PIs may not spend more than 20% of direct costs per year on equipment purchases. All equipment purchases must be itemized during the full application process. Equipment not approved in the original proposal requires ADA written approval before being purchased. **Equipment purchases are not permitted in the final year of the award.**

Other Expenses
Other expenses must be itemized. Some examples of additional expenses eligible to be included in this category include:

- Travel to diabetes-related scientific meetings (limit of $5,000 per year)
- Publication costs (page charges, reprint costs)
- Books ($500 limit)
- Animal housing and acquisition costs

Prohibited Expenses
The following items cannot be purchased with award funds:

- Rent for office or lab space
- Computer hardware or other smart devices (e.g., desktop, laptop, printer, iPad, smart phone)
- Telephone or internet service
- Non-technical (e.g., custodial, or administrative) support
- Tuition
- Relocation costs
- Memberships and subscriptions (including ADA Professional Section membership)
- IRB or IACUC administration fees
- Grantsmanship consultant fees
- Visa or legal fees
- Office supplies
- Liability insurance

This is not a complete list. Any questions about whether a particular item or service may be purchased with direct costs should be referred to the ADA’s Research Programs Office. **The ADA reserves the right to refuse to pay for items or services with direct costs.** Unsanctioned purchases will be deducted from the recipient’s grant.

Indirect Costs
Indirect costs are limited to 10% of direct costs, and the yearly total amount (directs plus indirect costs) cannot exceed $200,000 per year. For example, projects requesting $200,000 per year are maximally allowed indirect costs of $18,182 (at 10% of directs), with direct costs totaling $181,818.

Overlapping Funding
If additional, overlapping support for the Association funded project is obtained from any other source at any time, funds awarded by the Association will be terminated, and any remaining uncommitted funds must be returned.
II. Online Instructions

Letters of Inquiry and subsequent Invitation to Apply must be submitted online via the official Grant Management Site, available through the ADA’s website. Submissions outside the site will not be accepted.

Applicants must complete the online forms and upload the complete the applicable supporting documentation appropriate to the Letter of Inquiry (Research Plan) as a PDF attachment. Multiple attachments or other formats will not be accepted. All award guidelines and stipulations for preparing the Letter of Inquiry must be followed (e.g., supporting documents, page limits, font sizes).

Follow the steps below to create a new letter of inquiry in the Grant Management Site. If you have any difficulties accessing the site, contact grantquestions@diabetes.org for assistance.

1. Click Create a New Letter of Inquiry at the bottom of the section
2. Create a new user account, or log in using an existing account
3. Complete the Eligibility Quiz to confirm your eligibility status – be sure to respond candidly for accurate results, submissions that do not meet eligibility criteria will be administratively disapproved
4. After successful completion of the quiz, the letter of inquiry process will begin
5. You may leave the site at any point by clicking Save & Finish Later at the bottom of the screen
6. After saving your work, you can log out and complete your submission at a later time
7. To resume an in-progress letter of inquiry, access ADA’s website and select Grant Management Site on the navigation menu

Required details for each section of the online form are outlined below.

A. Principal Investigator

Contact Information
The applicant must provide the institution’s full legal name where the research will be conducted. Incorrect or incomplete information may cause a delay in letter of inquiry and award notification. Do not abbreviate the institution’s name.

ORCID Identifier
ORCID (Open Researcher and Contributor ID) provides a unique, persistent identifier for researchers that supports automated linkages to the investigator’s digital research output. PIs are required to have an ORCID identifier at the time of submission. Registration is available free of charge.

American Diabetes Association Membership
Award recipients are required to become members of and/or maintain membership in the Professional Section of the American Diabetes Association for the duration of their award. The membership fee cannot be paid with ADA grant funds. If selected for funding, the PI must submit proof of ADA membership prior to award activation. Membership is not required at the time of letter of inquiry submission.

Work Permission
All investigators must have permission to legally work in the United States. Institutional confirmation of work permission will be required for all applicants.
B. **Requested Budget**

Enter the requested total amount for the award.

C. **Project Details**

**Resubmissions**

Resubmissions will be accepted from applicants eligible to re-apply. See eligibility considerations and resubmission requirements below.

If the LOI is a resubmission, please enter the grant reference number assigned to the original application (example: 7-22-ICTSHD-00). All invited resubmissions are required to upload a copy of the resubmission invitation email.
Title of Proposal
Only the first letter of the title’s first word should be capitalized. The title of the proposal should not have symbols, such as “β.” Instead of the symbol, type the full name. For example, instead of “β,” type “beta.” The Grant Management Site cannot support symbols, and any non-ASCII characters will be converted to question marks (“?”) upon submission.

D. Project Summary

Research Type
Characterize the proposed research as clinical or translational.

Clinical research is defined as research where the effect of health disparities on diabetes and its complications is evaluated, and includes therapeutic interventions, health services/care delivery research and epidemiological research aimed at identifying the distribution and determinants of disease in a population.

Translational research supported through this mechanism will typically involve expertise, collaboration and engagement across disciplines, and falls into two broad categories, (1) translating basic biological discoveries about how chronic discrimination can alter diabetes metabolism into clinical applications that improve human health, and (2) accelerating the translation of advances from research in health disparities on diabetes and its complications to the community setting or enhancing the adoption of best practices in patient care.

Diabetes Type of Proposed Research
Select the diabetes category relevant to the proposed research:

- Both Type 1 and Type 2 Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Obesity
- Pre-diabetes/insulin resistance
- Monogenic

Therapeutic Goal
Indicate the ultimate therapeutic goal of the research being proposed:

- Cure Diabetes
- Manage Diabetes
- Prevent Diabetes
- N/A

Research Program Area
Select up to three program areas that describe the type of research being proposed.
Scientific Abstract
(250-word maximum)
The scientific abstract must be a technical description of the proposed work that includes a background, hypothesis, supporting rationale, specific aims, research design, and relevance to a cure, prevention, and/or treatment of diabetes. The abstract should be written in the third person.

Abstracts should not include symbols, such as “α.” The Grant Management Site cannot support special characters, and any non-ASCII symbols will be converted to question marks (“?”) upon submission. Use the full term instead of the symbol, e.g., used the term “alpha” instead of “α”.

Lay Abstract
(250-word maximum)
The lay abstract must be a non-technical description of the proposed work, not to exceed 250 words. This description must not repeat the scientific abstract. Instead, use non-technical language so the general public that does not have a scientific background can understand. The non-technical description must include the study’s purpose and significance to diabetes. Do not include confidential information in the lay abstract because if the award is funded, the lay abstract will become public information. The lay abstract must be written in the third person.

Abstracts should not include symbols, such as “β.” The Grant Management Site cannot support special characters, and any non-ASCII symbols will be converted to question marks (“?”) upon submission. Use the full term instead of the symbol, e.g., use the term “beta” instead of “β”.

RFA Alignment
(250-word maximum)
Applicants must detail how the proposed research directly aligns with the goal and scope of the RFA and will have a significant impact (“move the needle”) on outcomes in those individuals living with diabetes.
III. Research Plan

A. File Format

The required research plan template can be downloaded from the ADA grants website. 

Hard copies, multiple attachments, or other formats will not be accepted and will result in administrative disapproval.

B. Formatting Requirements

Submissions must abide by the following format specifications:

- **Font:** Use an Arial, Helvetica, Palatino Linotype, or Georgia typeface, a black font color, and a font size of 11 points or larger. (A Symbol font may be used to insert Greek letters or special characters; the font size requirement still applies.) Type density, including characters and spaces, must at least 15 characters per inch. Since font size can appear larger on a computer screen, applicants are responsible for printing the PDF and measuring the font size. Submissions that do not adhere to these formatting requirements will not be reviewed.

- **Font for Figures, Graphs, Diagrams, Charts, Tables, Figure Legends, and Footnotes:** Label fonts may be a smaller point size, but must be in a black font color, readily legible, and follow the font typeface requirement. Color can be used in figures; however, all text must be in a black font color, clear and legible.

- **Margins:** Margins must be at least one-half inch.

- **Spacing:** Single-spacing is acceptable.

- **Legibility:** The PDF document should be easy to read. Reviewers read many submissions and respond favorably to clear, organized, well-written proposals.

C. Research Plan Contents

Specifications for content are described below.

1) **Research Plan (2-page maximum)**

Plan of the proposed research following the outline below. Figures and tables must be included within the two-page maximum limit. **LOIs that do not conform to these guidelines or exceed the maximum page limits within each section will be administratively disapproved.**

The overall proposal should be kept as brief as possible while still presenting the complete research plan. As a panel of experts in the field will review proposals, established methods may be referred to by reference rather than described in detail in the proposal. New methodology or novel approaches should be described in detail. In general, the scope of the proposal should match the program budget. The following format must be used for the Research Plan:

   a) **Specific Aims**

   Provide an overview of the proposed research, including a high-level summary of the problem, relevance to the disease state and theoretical framework. Concisely state the goals of the work and summarize the expected outcome(s).
b) **Significance**

Explain the importance of the problem or barrier to progress in the field of diabetes research addressed by the project, and the necessity of the proposed work to the development of new knowledge in this research area. Describe how the expected results will make a clear and significant contribution to the field of scientific knowledge, technical capabilities and/or clinical practice for people with diabetes.

c) **Research Approach**

Describe the overall strategy, methodology and analyses used to accomplish the specific aims of the project, integrating any preliminary data into discussion of the specific aim(s). Discuss any potential pitfalls and outline contingency plans. Particularly if the project is in the early stages of development, address the management of any high-risk aspects of the proposed work and describe strategies to establish feasibility. Expected outcomes should also be provided. Figures and tables must be included within the page limit.

*Submissions that are incomplete or do not adhere to section page limits will be administratively disapproved.*
IV. Letter of Inquiry Submission

To complete the online submission process at a later date, select **Save and Finish Later** at any point during the online submission process. Saved submissions can be accessed through the Grant Management Site.

Applicants must select **Review & Submit** when ready to submit. Changes cannot be made to submissions. The PI must have approval from the sponsoring institution prior to submission and must agree to accept responsibility for the scientific and technical conduct of the research project and accepts all terms and conditions of the award.

---

**Submission Issues? Troubleshooting Tips**

1. The Grant Management Site utilizes cookies on your computer. To access the online letter of inquiry, you may need to:
   
   a. Close all open browser windows
   b. Clear your cache and cookies
   c. Open a new browser window
   
   d. Paste the link below into the address bar: [www.grantrequest.com/SID_320](http://www.grantrequest.com/SID_320)
   e. Change your security setting to allow cookies

2. Submissions will not be saved unless applicant creates an account before beginning the process. Submissions created without user accounts will have to start over with the online process.

3. Changes cannot be made to submissions. Be sure to proofread your letter of inquiry carefully prior to submission.

---

Electronic submissions must be submitted by **5:00 PM Eastern Time** on the deadline date. Any questions regarding the grant process should be sent to [grantquestions@diabetes.org](mailto:grantquestions@diabetes.org).

---

V. Questions? Contact Us

- Website URL: [https://professional.diabetes.org/content-page/current-funding-opportunities](https://professional.diabetes.org/content-page/current-funding-opportunities).
- For any questions, please contact [grantquestions@diabetes.org](mailto:grantquestions@diabetes.org).